CS12088

A hepatitis B nucleocapsid assembly modulator, is exclusively discovered by the company with global patent protection. The preclinical study results of CS12088 have shown that it can maintain nanomolar antiviral activity against hepatitis B of different genotypes, with liver targeting characteristics and good safety and tolerability. The approval letter for the clinical trial of CS12088 tablets was issued in Feb. 2025.

CS12192

A highly selective JAK3 kinase inhibitor exclusively discovered by the company with global patent protection, partially inhibits JAK1 and TBK1 kinases, and its indications under development are autoimmune diseases. At present, the company has completed the phase 1 clinical trial of CS12192 for the treatment of rheumatoid arthritis in China.

The company has deployed a number of R&D projects with differentiated advantages and global competitiveness in five major fields including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antiviral diseases, and maintains a portfolio of candidate drug molecules with the Best in class potential, such as CS1011, CS08399, and CS25141, and these projects/products will also bring the core value of the company in the future.

Please scan the QR code below by Wechat and follow the official accounts platform of "Chipscreen Biosciences"to get more information about the latest R&d progress.